Business Wire

Astellas Announces Results from the First Head to Head Study Comparing QUTENZATM (Capsaicin 8% Patch) with Current Standard of Care in Patients with Peripheral Neuropathic Pain

Del

Astellas Pharma Europe Ltd. today announced the publication in the European Journal of Pain of a head to head, non-inferiority study that compared the capsaicin 8% patch (QUTENZATM) with pregabalin capsules (flexible, optimised dose) in adult patients with peripheral neuropathic pain (PNP)1. The authors conclude that the capsaicin 8% patch provided non-inferior pain relief compared with pregabalin, in addition to a shorter median time to pain relief, fewer systemic side effects and greater treatment satisfaction.1

The ELEVATE study* had a randomised, open-label, 8-week, non-inferiority design and included 559 adults with moderate-to-severe PNP. Patients were randomised to receive either a single treatment with the capsaicin 8% patch or daily administration of an optimised dose of oral pregabalin. The study met its primary endpoint of non-inferiority for pain relief, defined by a ≥30% decrease in mean numeric pain rating scale (NPRS) score from baseline to Week 8.1 The 30% responder rate was 55.7% in the capsaicin 8% patch arm, compared with 54.5% in the pregabalin arm (odds ratio [95% CI]: 1.03 [0.71, 1.50]).1 Moreover, the median time to pain relief with the capsaicin 8% patch was 7.5 days, compared with 36.0 days [including titration period] with pregabalin (hazard ratio [95% CI]: 1.68 [1.35, 2.08]; p<0.0001).1

Commenting on the results of ELEVATE, Professor Maija Haanpää, Principal Study Investigator, Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland said: “This is an important and well-conducted study that was designed to mimic everyday practice, allowing those patients randomised to the pregabalin arm to be individually titrated to the optimal tolerated dose. We found that topical treatment with the capsaicin 8% patch was non-inferior to the current standard of care. This means that there is now another treatment option for people with peripheral neuropathic pain, especially those patients who are very sensitive to the side effects of systemic medication or for those who do not wish to take tablets every day.”

Secondary endpoints included optimal therapeutic effect (assessed using a composite endpoint including pain relief, adverse events and treatment discontinuation), median time to pain relief (defined as when 50% of patients had a 30% reduction in NPRS score) and treatment satisfaction.1 Results showed a difference in patient perception of treatment effectiveness, side effects and treatment satisfaction that were in favour of the capsaicin 8% patch.1

“Some patients may still receive inadequate pain management and have to balance effective pain relief and the side effects of their medication. The capsaicin 8% patch is applied topically and hence has shown less systemic side effects than seen with oral medications. There is a need to tailor treatment to individual patients and these data show that the capsaicin 8% patch is an efficacious agent to manage patients with peripheral neuropathic pain,” commented Dr Andreas Karas, Senior Director, Medical Affairs, Astellas Pharma EMEA.

The proportion of drug-related treatment emergent adverse events (TEAEs) was 54.5% for pregabalin and 61.3% for the capsaicin 8% patch.1 TEAEs leading to permanent discontinuation of study drug were only reported in the pregabalin arm (n=24, 8.5%).1 With the capsaicin 8% patch, the majority of drug-related TEAEs were transient and related to the application site.1 In comparison, pregabalian was associated with systemic adverse drug reactions (ADRs).1 Systemic ADRs ranged from 0-1.1% for the capsaicin patch and 2.5-18.4% for pregabalin.1

In September this year, the European Commission granted approval for a label extension for QUTENZATM (capsaicin 8% patch) for the treatment of peripheral neuropathic pain in adults, including adult diabetic patients with peripheral neuropathic pain, either alone or in combination with other medicinal products for pain.2

– Ends –

Notes to Editors

About neuropathic pain

Neuropathic pain, a type of pain caused by a lesion or disease of the somatosensory nervous system,3 is a well-characterised neurological condition, which has been estimated to affect approximately 7–8% of the general population in Europe.4,5 The pain intensity varies and can impact a person’s quality of life, general health and social and economic wellbeing.6

About QUTENZA (capsaicin 8% patch)

The capsaicin 8% patch is approved by the European Medicines Agency for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.2 The capsaicin 8% patch is approved for use in 27 countries across Europe as of the end of 2014.

The capsaicin 8% patch delivers a high-dose of a synthetic form of capsaicin directly to the damaged pain sensing nerves in the skin that are the source of neuropathic pain. Applied to the area of pain, the high concentration of capsaicin contained in the patch is released into the skin where it overstimulates the pain sensing nerves. Overstimulating the pain sensing nerves makes them become “defunctionalised,” effectively reducing their spontaneous activity and making them unresponsive to stimuli that normally cause pain for patients with peripheral neuropathic pain.7 As a result of treatment-related discomfort, transient increases in blood pressure may occur during and shortly after treatment with the capsaicin 8% patch.8 There have been reported cases of burns, including second degree burns, in patients treated with capsaicin patches.9

Important information for the capsaicin 8% patch, including safety information, is included in the full Summary of Product Characteristics at: https://www.medicines.org.uk/emc/medicine/23156.

About Astellas

Astellas Pharma Europe Ltd. operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas’ presence in Europe also includes an R&D site and three manufacturing plants.

References:

1. Haanpää M, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. European Journal of Pain, 2015; epub ahead of print. doi:10.1002/ejp.731

2. QUTENZATM, Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/23156 (Accessed November 2015).

3. Jensen, Troels S, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204-5.

4. Torrance N, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-289.

5. Bouhassira D, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-387.

6. NICE clinical guidelines 173 Neuropathic Pain – pharmacological management in non-specialist settings. November 2013. Available from: https://www.nice.org.uk/guidance/cg173/chapter/Introduction (Accessed November 2015).

7. Anand P et al. Topical capsacin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107(4):490-502.

8. Backonja M, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7(12):1106-12.

9. European Medicines Agency (EMA). Qutenza European Public Assessment Report (EPAR). Doc. Ref.: EMEA/629172/2009 EMEA/H/C/909. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000909/WC500040448.pdf. (Accessed November 2015).

* Trial registration: ClinicalTrials.gov Identifier: NCT01713426

Contact information

Astellas Pharma EMEA
Alice Cronshaw
+44 (0)7768 424046
or
Red Door Unlimited
Kimberly Santiago
+44 (0)208 392 8091

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Project Bronze: Sale of the Pradera European Retail Fund 2 Portfolio17.1.2018 23:38Pressemelding

An affiliate of MCAP Global Finance (UK) LLP ("MCAP") has completed the acquisition of a portfolio of six shopping centres in Spain and Italy, totalling 90,000 sqm (the “Bronze Portfolio”). Terms of the transaction were not disclosed. Formerly owned by the Pradera European Retail Fund 2 (the “Fund”), managed by Pradera, the Bronze Portfolio includes Formia: Itaca Shopping Centre, a 23,000 sqm shopping centre fully let and anchored by a Panorama hypermarket, located approximately 90km northwest of Naples; and Viterbo: Tuscia Shopping Centre, a 17,000 sqm shopping centre fully let and anchored by Coop, Italy’s largest supermarket chain, located circa 80km northwest of Rome. The transaction provided an exit for the Fund’s unitholders. Pradera will continue to serve as asset manager of the Bronze Portfolio on behalf of MCAP. Accord Europe Limited served as the exclusive financial advisor to the Fund. MCAP was self-advised. ABOUT PRADERA Pradera is a market leading specialist fund and asset

CES Asia 2018 Call for Speaker Proposals Now Open17.1.2018 21:37Pressemelding

The Consumer Technology Association (CTA) today announced that its Call for Speaker Proposals for CES Asia 2018 is now open. CES Asia seeks abstracts and speakers for the CES Asia conference program. Interested candidates, including subject matter experts from throughout Asia and across industries, have the opportunity to submit a conference proposal through February 14, 2018. Industry executives, futurists and visionaries in vehicle technology, financial tech, smart cities and other target technologies are encouraged to apply. Accepted proposals will be notified by April 2, 2018. Please review the full list of conference themes, submission guidelines and speaker overview before submitting. The CES Asia conference programming features over 30 conference sessions with more than 115 highly sought after industry experts from around the globe. CES Asia speakers present to an audience of high-level industry professionals, including 1,200 members of the global media. More than 40,000 people

STATS Announces Carl Mergele as Chief Executive Officer17.1.2018 17:04Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, announced the hiring of seasoned software executive, Carl Mergele as Chief Executive Officer. Mergele has extensive experience leading and growing software companies, providing world class products and excellent customer service across a number of sectors. In November 2016, Mergele was a software executive of publicly traded NYSE-company Lexmark International, Inc. which was sold to a consortium of private equity investors for $3.6 billion, following a number of software acquisitions in the preceding four years. In addition to leading software companies as CEO, including Vista-owned companies, Mergele has served as a board member to nearly two-dozen corporate entities. Mergele will oversee the company’s next phase of growth, empowering STATS’ customers—the most innovative and successful sports teams, leagues, and brands—with the best data, intelligence and technology, giving them an edge over their competition. “I am t

Intersolar and Power2Drive Europe 2018: Solar Power Generates Mobility17.1.2018 15:40Pressemelding

E-mobility is much more than just the clean mobility solution of the future. When electric vehicles are fueled by solar power, it also drives the deployment of photovoltaics forward. Intersolar Europe, the world’s leading exhibition for the solar industry, and Power2Drive Europe, the new exhibition for e-mobility and charging infrastructure, held June 20–22, 2018 in Munich, Germany under the umbrella of The smarter E Europe, will thus showcase the diverse prospects created for the environment by the combination of PV and e-mobility. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117005988/en/ Solar Power generates mobility (Photo: Solar Promotion GmbH) Electric vehicles can be driven and charging stations can be fed with electricity from PV systems, making e-mobility a driver of the PV market. Ideally, electric vehicles are charged with solar power directly from the owner’s roof. For example, a PV system with a capacity of

Ascend Performance Materials Announces Price Increase for Nylon 6,6 Polymers, Compounds and Fibers17.1.2018 15:22Pressemelding

Ascend Performance Materials announced today a price increase for its nylon 6,6 polymers, compounds and fibers due to escalating raw material costs. The price increase takes effect Feb. 1, 2018, and includes the following price changes: Materials Geography Price Increase Terms Nylon 6,6 polymers, compounds and fibers North America $0.10/lb. As contracts allow Non-contract business – price determined on an order-by-order basis Nylon 6,6 polymers, compounds and fibers Europe €0.20/kg. As contracts allow Non-contract business – price determined on an order-by-order basis Nylon 6,6 polymers, compounds and fibers Asia $0.22/kg. As contracts allow Non-contract business – price determined on an order-by-order basis Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 r

Mavenir Announces Virtualized Media Breakout Controller, Bringing 5G Edge Architectures to Legacy Networks17.1.2018 14:00Pressemelding

Mavenir, focused on transforming mobile network economics for Communications Service Providers, today announced its virtualized Media Breakout Controller (vMBC), a single white box routing platform that enables carriers to host virtual Routing, Firewall, and User plane data offload. Today’s networks, whether 3G, 4G or 5G, are under pressure to provide increased bandwidth in support of LTE and its frequency combinations, and reduce latency for network interaction, resulting in a continual need to increase capacity for traffic transported through the core of the network. Multi-Access Edge Computing standardization (MEC) is trying to resolve some of these issues by placing compute functionality at the edge but it is still mostly controlled from the core, based on conventional centralized architectures. The ability to scale network functionality using virtual elements and COTS HW platforms allows network functionality to be deployed at any location. Mavenir’s innovative solution offers the

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom